These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2453874)

  • 1. Asperlicin, a nonpeptidal cholecystokinin receptor antagonist, attenuates sodium taurocholate-induced acute pancreatitis in rats.
    Wisner JR; Renner IG
    Pancreas; 1988; 3(2):174-9. PubMed ID: 2453874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus.
    Chang RS; Lotti VJ; Monaghan RL; Birnbaum J; Stapley EO; Goetz MA; Albers-Schönberg G; Patchett AA; Liesch JM; Hensens OD
    Science; 1985 Oct; 230(4722):177-9. PubMed ID: 2994227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
    Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M
    Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the specific cholecystokinin antagonist L 364,718 in experimental acute pancreatitis in the rat.
    Sjövall S; Ahrén B; Stenram U
    Eur Surg Res; 1988; 20(5-6):325-9. PubMed ID: 2465158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asperlicin: a unique nonpeptide cholecystokinin antagonist.
    Zucker KA; Adrian TE; Zdon MJ; Ballantyne GH; Modlin IM
    Surgery; 1987 Aug; 102(2):163-70. PubMed ID: 2441481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of endogenous cholecystokinin and cholecystokinin-A receptors in the development of acute pancreatitis in rats.
    Tachibana I; Shirohara H; Czako L; Akiyama T; Nakano S; Watanabe N; Hirohata Y; Otsuki M
    Pancreas; 1997 Mar; 14(2):113-21. PubMed ID: 9057182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholecystokinin augmentation of 'surgical' pancreatitis. Benefits of receptor blockade.
    Modlin IM; Bilchik AJ; Zucker KA; Adrian TE; Sussman J; Graham SM
    Arch Surg; 1989 May; 124(5):574-8. PubMed ID: 2469410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of endogenous cholecystokinin in pancreatic regeneration after cerulein-induced acute pancreatitis.
    Jurkowska G; Grondin G; Morisset J
    Pancreas; 1992; 7(3):295-304. PubMed ID: 1594550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of somatostatin analogue and cholecystokinin receptor antagonist on bile-induced acute canine pancreatitis.
    Ko TC; Bertram MF; Prinz RA; Castelli M; Djuricin G; Jacobs HK
    Am Surg; 1992 Apr; 58(4):213-9. PubMed ID: 1375011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholecystokinin antagonist prevents hyperamylasemia and improves pancreatic exocrine function in cerulein-induced acute pancreatitis.
    Murayama KM; Drew JB; Nahrwold DL; Joehl RJ
    Pancreas; 1990 Jul; 5(4):439-44. PubMed ID: 1696383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cholecystokinin receptor antagonist L-364,718 reduces taurocholate-induced pancreatitis in rats.
    Kim KH; Lee MG; Kim DG
    Int J Pancreatol; 1996 Dec; 20(3):205-11. PubMed ID: 9013282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
    Jia D; Yamamoto M; Otsuki M
    World J Gastroenterol; 2015 Jul; 21(25):7742-53. PubMed ID: 26167074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide and cholecystokinin antagonist reduce edema in obstruction-induced acute pancreatitis.
    Toriumi Y; Samuel I; Wilcockson DP; Turkelson CM; Solomon TE; Joehl RJ
    J Lab Clin Med; 1993 Oct; 122(4):450-4. PubMed ID: 8228560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
    Tani S; Itoh H; Koide M; Okabayashi Y; Otsuki M
    Pancreas; 1993 Jan; 8(1):109-15. PubMed ID: 7678322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice].
    Kobayashi M; Shinagawa K; Sugiura M; Nagasawa T; Akahane M; Ajisawa Y
    Nihon Yakurigaku Zasshi; 1996 Apr; 107(4):183-95. PubMed ID: 8690301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.
    Niederau C; Liddle RA; Ferrell LD; Grendell JH
    J Clin Invest; 1986 Oct; 78(4):1056-63. PubMed ID: 2428840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the CCK receptor antagonist CR 1409 on bile reflux pancreatitis in the opossum.
    Larsen F; Schlarman D; Andrus CC; Kaminski DL
    Pancreas; 1991 May; 6(3):291-7. PubMed ID: 1713673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cholecystokinin in cholestyramine-induced changes of the exocrine pancreas.
    Koop I; Lindenthal M; Schade M; Trautmann M; Adler G; Arnold R
    Pancreas; 1991 Sep; 6(5):564-70. PubMed ID: 1946314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a cholecystokinin receptor antagonist lorglumid on the proteinase-antiproteinase balance in taurocholate acute experimental pancreatitis (AEP) in rats.
    Kosidło S; Rydzewska G; Gabryelewicz A
    Mater Med Pol; 1992; 24(4):223-6. PubMed ID: 1308047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.